Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort
Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment access and awareness.
